Mr. Otto Rasmussen will step down as CFO of BioPorto A/S at January 31, 2015 to become Finance Director of Xellia Pharmaceuticals, a company owned by Novo A/S.
Peter Mørch Eriksen, CEO of BioPorto, said: “Otto has been an important part of the first phase of BioPorto’s turnaround, building a solid finance department and streamlining business procedures. With a strong capital base and fully functional back-office, we now turn our attention to the commercialization of our diagnostic tests and antibodies. Therefore, Otto has decided it was time to take on new challenges. I would like to thank him for our great cooperation in BioPorto and wish him good luck in his new position at Xellia.”
Mrs. Birgitte Svendsen has been appointed interim CFO of BioPorto from February 1, 2015. Birgitte is a former accountant at Arthur Andersen and has previously also held positions as controller and financial director in companies like Novo Nordisk, Carat Danmark and Tiscali/World Online. Today, Birgitte is partner and CEO of Pecunia Consult.
Going forward, the executive management at BioPorto A/S will be constituted by Peter Mørch Eriksen, CEO.
The above changes to the executive management does not affect revenue and earnings guidance announced by BioPorto for the 2014 financial year.
Further details:
Peter Mørch Eriksen, CEO
Tel.: 45 29 00 00, e-mail investor@bioporto.com
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underdiagnosed diseases, including NGAL test for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto is headquartered in Copenhagen, Denmark and is listed on the NASDAQ Copenhagen stock exchange.
